14.1M XNAS Volume
XNAS 19 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Simonian Nancy A. | Director | 02 Dec 2024 | 37,070 | 4,000 (0%) | 0% | 0.3 | 10,016 | Common Stock | |
| Simonian A. Nancy | Director | 25 Nov 2024 | 134,713 | 41,070 (0%) | 0% | 0.3 | 35,739 | Common Stock | |
| Gerald E. Quirk | Chief Legal & Compliance Offic | 19 Nov 2024 | 46,657 | 0 (0%) | 0% | 0.2 | 10,321 | Common Stock | |
| David A. Roth | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.20 per share. | 18 Nov 2024 | 12,099 | 0 (0%) | 0% | 0.2 | 2,382 | Common Stock |
| Kristin Stephens | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 0.22 per share. | 18 Nov 2024 | 36,133 | 0 (0%) | 0% | 0.2 | 7,949 | Common Stock |
| Conley Chee | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 0.20 per share. | 18 Nov 2024 | 134,797 | 0 (0%) | 0% | 0.2 | 26,932 | Common Stock |
| Jason Haas | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.21 per share. | 18 Nov 2024 | 137,803 | 0 (0%) | 0% | 0.2 | 28,980 | Common Stock |
| Nancy A. Simonian | Director | 31 Oct 2024 | 40,125 | 0 | - | - | Restricted Stock Units | ||
| Nancy A. Simonian | Director | 31 Oct 2024 | 40,125 | 175,783 (0%) | 0% | - | Common Stock | ||
| David A. Roth | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 31 Oct 2024 | 6,776 | 12,099 (0%) | 0% | 2.1 | 14,162 | Common Stock |
| David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 18,875 | 0 | - | - | Restricted Stock Units | |
| David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 18,875 | 18,875 (0%) | 0% | - | Common Stock | |
| Kristin Stephens | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 31 Oct 2024 | 6,104 | 36,133 (0%) | 0% | 2.1 | 12,757 | Common Stock |
| Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 17,000 | 42,237 (0%) | 0% | - | Common Stock | |
| Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 17,000 | 0 | - | - | Restricted Stock Units | |
| Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 17,000 | 0 | - | - | Restricted Stock Units | |
| Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 17,000 | 139,504 (0%) | 0% | - | Common Stock | |
| Conley Chee | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 31 Oct 2024 | 8,707 | 130,797 (0%) | 0% | 2.1 | 18,198 | Common Stock |
| Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 18,875 | 0 | - | - | Restricted Stock Units | |
| Jason Haas | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 31 Oct 2024 | 5,624 | 137,803 (0%) | 0% | 2.1 | 11,754 | Common Stock |
| Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 18,875 | 143,427 (0%) | 0% | - | Common Stock | |
| Gerald E. Quirk | Chief Legal & Compliance Offic | 30 Sep 2024 | 10,000 | 49,757 (0%) | 0% | - | Common Stock | ||
| Gerald E. Quirk | Chief Legal & Compliance Offic | 30 Sep 2024 | 10,000 | 20,000 | - | - | Restricted Stock Units | ||
| Gerald E. Quirk | Chief Legal & Compliance Offic | 30 Sep 2024 | 3,100 | 46,657 (0%) | 0% | 2.1 | 6,510 | Common Stock | |
| Srinivas Akkaraju | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,667 | 2,667 | - | - | Restricted Stock Units | |
| Srinivas Akkaraju | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,667 | 9,333 (0%) | 0% | - | Common Stock | |
| Richard A. Young | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,667 | 2,667 | - | - | Restricted Stock Units | |
| Richard A. Young | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,667 | 10,667 (0%) | 0% | - | Common Stock | |
| Conley Chee | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.71 per share. | 10 Sep 2024 | 50,000 | 122,504 (0%) | 0% | 1.7 | 85,420 | Common Stock |
| Conley Chee | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.51 per share. | 10 Sep 2024 | 50,000 | 72,504 (0%) | 0% | 1.5 | 75,260 | Common Stock |
| Jason Haas | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.58 per share. | 10 Sep 2024 | 19,293 | 79,208 (0%) | 0% | 1.6 | 30,446 | Common Stock |
| Jason Haas | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.55 per share. | 10 Sep 2024 | 35,363 | 59,915 (0%) | 0% | 1.5 | 54,788 | Common Stock |
| Jason Haas | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.68 per share. | 10 Sep 2024 | 45,344 | 124,552 (0%) | 0% | 1.7 | 76,006 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 5.12 per share. | 28 Jun 2024 | 34,837 | 8,000 (0%) | 0% | 5.1 | 178,365 | Common Stock |
| Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Marsha H. Fanucci | Director | 05 Jun 2024 | 4,000 | 16,000 (0%) | 0% | 0 | Common Stock | ||
| Marsha H. Fanucci | Director | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director | 05 Jun 2024 | 4,000 | 135,658 (0%) | 0% | 0 | Common Stock | ||
| Peter Wirth | Director | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | ||
| Peter Wirth | Director | 05 Jun 2024 | 4,000 | 16,000 (0%) | 0% | 0 | Common Stock | ||
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 4,000 | 33,189 (0%) | 0% | 0 | Common Stock | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 4,000 | 42,837 (0%) | 0% | 0 | Common Stock | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 4,000 | 16,000 (0%) | 0% | 0 | Common Stock | |
| Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Deborah L. Dunsire | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,000 | 0 | - | - | Restricted Stock Units | |
| Deborah L. Dunsire | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,000 | 12,000 (0%) | 0% | - | Common Stock | |
| Srinivas Akkaraju | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,000 | 0 | - | - | Restricted Stock Units | |
| Srinivas Akkaraju | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,000 | 6,666 (0%) | 0% | - | Common Stock | |
| David A. Roth | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.95 per share. | 03 Apr 2024 | 10,451 | 0 (0%) | 0% | 4.9 | 51,732 | Common Stock |
| Nancy A. Simonian | Director | 31 Mar 2024 | 6,000 | 106,144 (0%) | 0% | - | Common Stock | ||
| Nancy A. Simonian | Director | 31 Mar 2024 | 39,566 | 79,134 | - | - | Restricted Stock Units | ||
| Nancy A. Simonian | Director | 31 Mar 2024 | 6,000 | 12,000 | - | - | Restricted Stock Units | ||
| Nancy A. Simonian | Director | 31 Mar 2024 | 14,052 | 131,658 (0%) | 0% | 5.1 | 71,946 | Common Stock | |
| Nancy A. Simonian | Director | 31 Mar 2024 | 39,566 | 145,710 (0%) | 0% | - | Common Stock | ||
| David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 2,000 (0%) | 0% | - | Common Stock | |
| David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 13,333 | 15,333 (0%) | 0% | - | Common Stock | |
| David A. Roth | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.12 per share. | 31 Mar 2024 | 4,732 | 10,601 (0%) | 0% | 5.1 | 24,228 | Common Stock |
| David A. Roth | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.98 per share. | 31 Mar 2024 | 150 | 10,451 (0%) | 0% | 5.0 | 747 | Common Stock |
| David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 13,333 | 26,667 | - | - | Restricted Stock Units | |
| Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 11,666 | 23,334 | - | - | Restricted Stock Units | |
| Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Kristin Stephens | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.12 per share. | 31 Mar 2024 | 4,218 | 25,237 (0%) | 0% | 5.1 | 21,596 | Common Stock |
| Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 17,789 (0%) | 0% | - | Common Stock | |
| Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 11,666 | 29,455 (0%) | 0% | - | Common Stock | |
| Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 11,666 | 23,334 | - | - | Restricted Stock Units | |
| Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Conley Chee | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.12 per share. | 31 Mar 2024 | 3,500 | 22,504 (0%) | 0% | 5.1 | 17,920 | Common Stock |
| Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 14,338 (0%) | 0% | - | Common Stock | |
| Conley Chee | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 11,666 | 26,004 (0%) | 0% | - | Common Stock | |
| Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 15,951 (0%) | 0% | - | Common Stock | |
| Jason Haas | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.12 per share. | 31 Mar 2024 | 4,732 | 24,552 (0%) | 0% | 5.1 | 24,228 | Common Stock |
| Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 13,333 | 26,667 | - | - | Restricted Stock Units | |
| Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 13,333 | 29,284 (0%) | 0% | - | Common Stock | |
| Gerald E. Quirk | Chief Legal & Compliance Offic | 27 Mar 2024 | 7,046 | 39,757 (0%) | 0% | 5.6 | 39,387 | Common Stock | |
| Gerald E. Quirk | Chief Legal & Compliance Offic | 27 Mar 2024 | 22,500 | 46,803 (0%) | 0% | - | Common Stock | ||
| Gerald E. Quirk | Chief Legal & Compliance Offic | 27 Mar 2024 | 22,500 | 0 | - | - | Restricted Stock Units | ||
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 4.42 per share. | 21 Dec 2023 | 904,977 | 1,786,427 (4%) | 2% | 4.4 | 3,999,998 | Common Stock |
| David A. Roth | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.95 per share. | 12 Dec 2023 | 6,287 | 0 (0%) | 0% | 5.0 | 31,121 | Common Stock |
| A. Roth David | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 06 Dec 2023 | 6,287 | 6,287 (0%) | 0% | 4.0 | 24,834 | Common Stock |
| Conley Chee | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2023 | 86,000 | 86,000 | - | - | Restricted Stock Units | |
| Simonian Nancy A. | Director | 01 Dec 2023 | 7,500 | 0 | - | - | Stock Option (right to buy) | ||
| A. Simonian Nancy | Director | 01 Dec 2023 | 30,399 | 0 | - | - | Stock Option (right to buy) | ||
| Simonian A. Nancy | Director | 01 Dec 2023 | 17,499 | 0 | - | - | Stock Option (right to buy) | ||
| Nancy Simonian A. | Director | 01 Dec 2023 | 29,399 | 0 | - | - | Stock Option (right to buy) | ||
| A. Simonian Nancy | Director | 01 Dec 2023 | 28,001 | 0 | - | - | Stock Option (right to buy) | ||
| David A. Roth | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 31 Jul 2023 | 7,348 | 0 (0%) | 0% | 4.0 | 29,025 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.50 per share. | 17 Jul 2023 | 689 | 6,661 (0%) | 0% | 3.5 | 2,412 | Common Stock |
| Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Marsha H. Fanucci | Director | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | ||
| Marsha H. Fanucci | Director | 01 Jun 2023 | 4,000 | 12,000 (0%) | 0% | 0 | Common Stock | ||
| Peter Wirth | Director | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | ||
| Peter Wirth | Director | 01 Jun 2023 | 4,000 | 12,000 (0%) | 0% | 0 | Common Stock | ||
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,000 | 29,189 (0%) | 0% | 0 | Common Stock | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,000 | 36,171 (0%) | 0% | 0 | Common Stock | |
| Mark J. Alles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Mark J. Alles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,000 | 12,000 (0%) | 0% | 0 | Common Stock | |
| Nancy A. Simonian | Director, President & CEO | 31 Mar 2023 | 6,000 | 75,272 (0%) | 0% | - | Common Stock | ||
| Nancy A. Simonian | Director, President & CEO | 31 Mar 2023 | 1,852 | 73,420 (0%) | 0% | 2.6 | 4,778 | Common Stock | |
| Nancy A. Simonian | Director, President & CEO | 31 Mar 2023 | 6,000 | 18,000 | - | - | Restricted Stock Units | ||
| David A. Roth | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 31 Mar 2023 | 623 | 7,348 (0%) | 0% | 2.6 | 1,607 | Common Stock |
| David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 7,971 (0%) | 0% | - | Common Stock | |
| David A. Roth | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 7,973 (0%) | 0% | - | Common Stock | |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Eric R. Olson | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 31 Mar 2023 | 623 | 7,350 (0%) | 0% | 2.6 | 1,607 | Common Stock |
| Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 5,088 (0%) | 0% | - | Common Stock | |
| Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Kristin Stephens | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 31 Mar 2023 | 623 | 4,465 (0%) | 0% | 2.6 | 1,607 | Common Stock |
| Conley Chee | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Conley Chee | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 31 Mar 2023 | 658 | 1,342 (0%) | 0% | 2.6 | 1,698 | Common Stock |
| Conley Chee | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 2,000 (0%) | 0% | - | Common Stock | |
| Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Jason Haas | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 31 Mar 2023 | 623 | 1,377 (0%) | 0% | 2.6 | 1,607 | Common Stock |
| Jason Haas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 2,000 (0%) | 0% | - | Common Stock | |
| Nancy A. Simonian | Director, President & CEO | 16 Feb 2023 | 118,700 | 118,700 | - | - | Restricted Stock Units | ||
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 35,000 | 35,000 | - | - | Restricted Stock Units | |
| Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 35,000 | 35,000 | - | - | Restricted Stock Units | |
| Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 35,000 | 35,000 | - | - | Restricted Stock Units | |
| Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Gerald E. Quirk | Chief Legal Officer | 11 Oct 2022 | 45,000 | 45,000 | - | - | Restricted Stock Units | ||
| Nancy A. Simonian | Director, President & CEO | 06 Oct 2022 | 115,000 | 115,000 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 06 Oct 2022 | 80,250 | 80,250 | - | - | Restricted Stock Units | ||
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 49,750 | 49,750 | - | - | Stock Option (right to buy) | |
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 37,750 | 37,750 | - | - | Restricted Stock Units | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 44,500 | 44,500 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 34,000 | 34,000 | - | - | Restricted Stock Units | |
| Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 34,000 | 34,000 | - | - | Restricted Stock Units | |
| Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 44,500 | 44,500 | - | - | Stock Option (right to buy) | |
| Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 44,500 | 44,500 | - | - | Stock Option (right to buy) | |
| Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 34,000 | 34,000 | - | - | Restricted Stock Units | |
| Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 37,750 | 37,750 | - | - | Restricted Stock Units | |
| Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 49,750 | 49,750 | - | - | Stock Option (right to buy) | |
| Timothy C. Tyson | Director | Purchase of securities on an exchange or from another person at price $ 6.37 per share. | 29 Sep 2022 | 14,000 | 24,932 (0%) | 0% | 6.4 | 89,186 | Common Stock |
| Timothy C. Tyson | Director | Purchase of securities on an exchange or from another person at price $ 5.72 per share. | 29 Sep 2022 | 2,932 | 10,932 (0%) | 0% | 5.7 | 16,770 | Common Stock |
| Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 8,000 | 8,000 (0%) | 0% | 0 | Common Stock | |
| Marsha H. Fanucci | Director | 16 Sep 2022 | 8,000 | 8,000 (0%) | 0% | 0 | Common Stock | ||
| Marsha H. Fanucci | Director | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | ||
| Peter Wirth | Director | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | ||
| Peter Wirth | Director | 16 Sep 2022 | 8,000 | 8,000 (0%) | 0% | 0 | Common Stock | ||
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 3,286 | 3,286 | - | - | Stock Option (right to buy) | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 8,000 | 8,000 (0%) | 0% | 0 | Common Stock | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 257 | 8,257 (0%) | 0% | - | Common Stock | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 2,232 | 2,232 | - | - | Stock Option (right to buy) | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 1,094 | 1,094 | - | - | Stock Option (right to buy) | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 2,191 | 2,191 | - | - | Stock Option (right to buy) | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 2,191 | 2,191 | - | - | Stock Option (right to buy) | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 2,848 | 2,848 | - | - | Stock Option (right to buy) | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 3,856 | 3,856 | - | - | Stock Option (right to buy) | |
| Timothy C. Tyson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 3,856 | 3,856 | - | - | Stock Option (right to buy) | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 691,489 | 691,489 | - | - | Warrants (right to buy) | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 8,000 | 8,000 | - | - | Restricted Stock Units | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 691,489 | 881,450 (2%) | 1% | - | Common Stock | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 8,000 | 8,000 | - | - | Restricted Stock Units | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Mark J. Alles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Mark J. Alles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 8,000 | 8,000 | - | - | Restricted Stock Units | |
| Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 8,000 | 8,000 (0%) | 0% | 0 | Common Stock | |
| Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Marsha H. Fanucci | Director | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | ||
| Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Peter Wirth | Director | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | ||
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Mark J. Alles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Amir H. Nashat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Nancy A. Simonian | Director, President & CEO | 01 Apr 2022 | 58,883 | 692,723 (1%) | 0% | 1.1 | 65,949 | Common Stock | |
| David A. Roth | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.12 per share. | 01 Apr 2022 | 27,281 | 59,719 (0%) | 0% | 1.1 | 30,555 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.12 per share. | 01 Apr 2022 | 27,266 | 59,734 (0%) | 0% | 1.1 | 30,538 | Common Stock |
| Kristin Stephens | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.12 per share. | 01 Apr 2022 | 14,115 | 30,885 (0%) | 0% | 1.1 | 15,809 | Common Stock |
| Nancy A. Simonian | Director, President & CEO | 15 Feb 2022 | 375,000 | 375,000 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 15 Feb 2022 | 400,000 | 400,000 | - | - | Restricted Stock Units | ||
| Nancy A. Simonian | Director, President & CEO | 15 Feb 2022 | 240,000 | 240,000 | - | - | Restricted Stock Units | ||
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 200,000 | 200,000 | - | - | Restricted Stock Units | |
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Restricted Stock Units | |
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Restricted Stock Units | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 200,000 | 200,000 | - | - | Restricted Stock Units | |
| Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Restricted Stock Units | |
| Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 200,000 | 200,000 | - | - | Restricted Stock Units | |
| Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Restricted Stock Units | |
| Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Restricted Stock Units | |
| Eric R. Olson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 05 Jan 2022 | 2,208 | 0 (0%) | 0% | 3.5 | 7,655 | Common Stock |
| Jason Haas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2021 | 750,000 | 750,000 | - | - | Stock Option (right to buy) | |
| Conley Chee | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Sep 2021 | 360,000 | 360,000 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 5.55 per share. | 01 Jul 2021 | 1,164 | 0 (0%) | 0% | 5.5 | 6,460 | Common Stock |
| Marsha H. Fanucci | Director | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | ||
| Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Peter Wirth | Director | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | ||
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Mark J. Alles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Amir H. Nashat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 15 Mar 2021 | 3,628 | 3,628 (0%) | 0% | 1.0 | 3,664 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 9.47 per share. | 15 Mar 2021 | 3,628 | 0 (0%) | 0% | 9.5 | 34,372 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 3,628 | 90,697 | - | - | Stock Option (right to buy) | |
| Nancy A. Simonian | Director, President & CEO | 17 Feb 2021 | 304,000 | 304,000 | - | - | Stock Option (right to buy) | ||
| Gerald E. Quirk | Chief Legal & Admin. Officer | 17 Feb 2021 | 94,000 | 94,000 | - | - | Stock Option (right to buy) | ||
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 119,000 | 119,000 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 94,000 | 94,000 | - | - | Stock Option (right to buy) | |
| Jeremy P. Springhorn | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 94,000 | 94,000 | - | - | Stock Option (right to buy) | |
| Joseph J. Ferra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 119,000 | 119,000 | - | - | Stock Option (right to buy) | |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 12.05 per share. | 16 Feb 2021 | 3,750 | 321,711 (0%) | 0% | 12.1 | 45,188 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 13.04 per share. | 08 Feb 2021 | 3,750 | 325,461 (0%) | 0% | 13.0 | 48,900 | Common Stock |
| Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 10,761 | 544,450 (1%) | 0% | 3.0 | 32,713 | Common Stock | |
| Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 4,988 | 280,012 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 14,168 | 79,165 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 10,761 | 21,524 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 4,988 | 563,606 (1%) | 0% | 10.1 | 50,329 | Common Stock | |
| Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 14,168 | 558,618 (1%) | 0% | 8.5 | 120,570 | Common Stock | |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.75 per share. | 16 Nov 2020 | 5,357 | 339,211 (0%) | 0% | 8.8 | 46,874 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.98 per share. | 16 Nov 2020 | 633 | 344,568 (0%) | 0% | 9.0 | 5,684 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.75 per share. | 19 Oct 2020 | 5,673 | 335,201 (0%) | 0% | 8.8 | 49,639 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.75 per share. | 15 Oct 2020 | 317 | 340,874 (0%) | 0% | 8.8 | 2,774 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 10.39 per share. | 15 Sep 2020 | 5,990 | 341,191 (0%) | 0% | 10.4 | 62,236 | Common Stock |
| Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 17 Aug 2020 | 744 | 1,433,199 (3%) | 0% | 13 | 9,672 | Common Stock |
| Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 13.10 per share. | 17 Aug 2020 | 158,583 | 1,274,616 (2%) | 0% | 13.1 | 2,076,724 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 12.59 per share. | 17 Aug 2020 | 5,990 | 347,181 (0%) | 0% | 12.6 | 75,414 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 17 Aug 2020 | 10,787 | 0 (0%) | 0% | 13 | 140,231 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 17 Aug 2020 | 10,787 | 10,787 (0%) | 0% | 1.0 | 10,895 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 17 Aug 2020 | 4,963 | 0 (0%) | 0% | 13 | 64,519 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 17 Aug 2020 | 4,963 | 4,963 (0%) | 0% | 1.0 | 5,013 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 10,787 | 94,325 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 4,963 | 105,112 | - | - | Stock Option (right to buy) | |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 11.85 per share. | 15 Jul 2020 | 5,990 | 353,171 (0%) | 0% | 11.9 | 70,982 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.72 per share. | 07 Jul 2020 | 1,753 | 0 (0%) | 0% | 11.7 | 20,538 | Common Stock |
| Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 11.01 per share. | 01 Jul 2020 | 4,627 | 1,433,943 (3%) | 0% | 11.0 | 50,966 | Common Stock |
| Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 11.15 per share. | 23 Jun 2020 | 54,972 | 1,438,570 (3%) | 0% | 11.1 | 612,850 | Common Stock |
| Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 11.07 per share. | 23 Jun 2020 | 48,775 | 1,493,542 (3%) | 0% | 11.1 | 539,788 | Common Stock |
| Srinivas Akkaraju | Director | Sale of securities on an exchange or to another person at price $ 11.11 per share. | 23 Jun 2020 | 50,953 | 1,542,317 (3%) | 0% | 11.1 | 565,930 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.75 per share. | 15 Jun 2020 | 5,990 | 359,161 (0%) | 0% | 8.8 | 52,413 | Common Stock |
| Marsha H. Fanucci | Director | 11 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | ||
| Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Peter Wirth | Director | 11 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | ||
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Mark J. Alles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Amir H. Nashat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 9.22 per share. | 15 May 2020 | 5,990 | 365,151 (0%) | 0% | 9.2 | 55,242 | Common Stock |
| Mark J. Alles | Director | Purchase of securities on an exchange or from another person at price $ 8.86 per share. | 13 May 2020 | 10,000 | 10,000 (0%) | 0% | 8.9 | 88,590 | Common Stock |
| Richard A. Young | Director | Sale of securities on an exchange or to another person at price $ 8.75 per share. | 15 Apr 2020 | 23,960 | 371,141 (0%) | 0% | 8.8 | 209,650 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.38 per share. | 18 Feb 2020 | 1,446 | 0 (0%) | 0% | 7.4 | 10,674 | Common Stock |
| Nancy A. Simonian | Director, President & CEO | 13 Feb 2020 | 294,000 | 294,000 | - | - | Stock Option (right to buy) | ||
| Gerald E. Quirk | Chief Legal & Admin. Officer | 13 Feb 2020 | 94,000 | 94,000 | - | - | Stock Option (right to buy) | ||
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 94,000 | 94,000 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 94,000 | 94,000 | - | - | Stock Option (right to buy) | |
| Jeremy P. Springhorn | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 94,000 | 94,000 | - | - | Stock Option (right to buy) | |
| Joseph J. Ferra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2020 | 94,000 | 94,000 | - | - | Stock Option (right to buy) | |
| Nancy A. Simonian | Director, President & CEO | 23 Dec 2019 | 33,429 | 1,037,095 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 23 Dec 2019 | 8,210 | 1,018,123 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 23 Dec 2019 | 10,762 | 1,026,333 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 23 Dec 2019 | 52,401 | 533,689 (1%) | 0% | 3.0 | 159,299 | Common Stock | |
| Mark J. Alles | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2019 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Jeremy P. Springhorn | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 4.97 per share. | 11 Nov 2019 | 10,121 | 35,000 (0%) | 0% | 5.0 | 50,268 | Common Stock |
| Jeremy P. Springhorn | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 4.99 per share. | 11 Nov 2019 | 9,879 | 24,879 (0%) | 0% | 5.0 | 49,328 | Common Stock |
| Richard A. Young | None | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 15 Aug 2019 | 2,300 | 417,801 (0%) | 0% | 10 | 23,000 | Common Stock |
| Richard A. Young | None | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 15 Aug 2019 | 22,700 | 395,101 (0%) | 0% | 10 | 227,000 | Common Stock |
| Marsha H. Fanucci | None | 11 Jun 2019 | 11,000 | 11,000 | - | - | Common Stock (right to buy) | ||
| Michael W. Bonney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Phillip A. Sharp | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Vicki L. Sato | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 11,000 | 11,000 | - | - | Common Stock (right to buy) | |
| Peter Wirth | None | 11 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | ||
| Srinivas Akkaraju | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Richard A. Young | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Amir H. Nashat | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Alice Tsang Shaw | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Srinivas Akkaraju | None | Purchase of securities on an exchange or from another person at price $ 7.50 per share. | 09 Apr 2019 | 533,332 | 1,593,270 (3%) | 1% | 7.5 | 3,999,990 | Common Stock |
| Srinivas Akkaraju | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 09 Apr 2019 | 133,333 | 133,333 | - | - | Common Stock Warrants (rights to buy) | |
| Nancy A. Simonian | Director, President & CEO | 12 Feb 2019 | 188,000 | 669,288 (1%) | 0% | 0 | Common Stock | ||
| Nancy A. Simonian | Director, President & CEO | 12 Feb 2019 | 285,000 | 285,000 | - | - | Stock Option (right to buy) | ||
| Gerald E. Quirk | Chief Legal & Admin. Officer | 12 Feb 2019 | 87,000 | 87,000 (0%) | 0% | 0 | Common Stock | ||
| Gerald E. Quirk | Chief Legal & Admin. Officer | 12 Feb 2019 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | ||
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 87,000 | 87,000 (0%) | 0% | 0 | Common Stock | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 87,000 | 87,000 (0%) | 0% | 0 | Common Stock | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Jeremy P. Springhorn | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 87,000 | 102,000 (0%) | 0% | 0 | Common Stock | |
| Jeremy P. Springhorn | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Joseph J. Ferra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 87,000 | 87,000 (0%) | 0% | 0 | Common Stock | |
| Joseph J. Ferra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2019 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Nancy A. Simonian | Director, President & CEO | 29 Nov 2018 | 12,084 | 481,288 (1%) | 0% | 3.0 | 36,735 | Common Stock | |
| Nancy A. Simonian | Director, President & CEO | 29 Nov 2018 | 23,454 | 872,657 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 29 Nov 2018 | 75,050 | 797,607 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 29 Nov 2018 | 12,084 | 785,523 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 29 Nov 2018 | 98,504 | 469,204 (1%) | 0% | 1.0 | 99,489 | Common Stock | |
| Marsha H. Fanucci | None | 14 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | ||
| Michael W. Bonney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Phillip A. Sharp | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Vicki L. Sato | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Peter Wirth | None | 14 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | ||
| Srinivas Akkaraju | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Richard A. Young | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Amir H. Nashat | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2018 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Joseph J. Ferra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2018 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Joseph J. Ferra | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2018 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Nancy A. Simonian | Director, President & CEO | 16 Feb 2018 | 285,000 | 285,000 | - | - | Stock Option (right to buy) | ||
| Gerald E. Quirk | Chief Legal Officer | 16 Feb 2018 | 11,666 | 11,666 | - | - | Stock Option (right to buy) | ||
| Gerald E. Quirk | Chief Legal Officer | 16 Feb 2018 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | ||
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2018 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2018 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Srinivas Akkaraju | None | Purchase of securities on an exchange or from another person at price $ 9.55 per share. | 31 Jan 2018 | 209,424 | 1,059,938 (3%) | 0% | 9.5 | 1,999,999 | Common Stock |
| Noubar B. Afeyan | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2017 | 24,527 | 0 (0%) | 0% | 0 | Common Stock | |
| Jeremy P. Springhorn | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 9.08 per share. | 15 Dec 2017 | 15,000 | 15,000 (0%) | 0% | 9.1 | 136,260 | Common Stock |
| Srinivas Akkaraju | None | Purchase of securities on an exchange or from another person at price $ 9.40 per share. | 12 Dec 2017 | 14,774 | 735,494 (2%) | 0% | 9.4 | 138,876 | Common Stock |
| Srinivas Akkaraju | None | Purchase of securities on an exchange or from another person at price $ 8.99 per share. | 12 Dec 2017 | 26,600 | 830,494 (3%) | 0% | 9.0 | 239,134 | Common Stock |
| Srinivas Akkaraju | None | Purchase of securities on an exchange or from another person at price $ 8.97 per share. | 12 Dec 2017 | 68,400 | 803,894 (3%) | 0% | 9.0 | 613,548 | Common Stock |
| Jeremy P. Springhorn | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2017 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Jeremy P. Springhorn | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2017 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Colleen DeSimone | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.04 per share. | 23 Oct 2017 | 550 | 550 (0%) | 0% | 3.0 | 1,672 | Common Stock |
| Colleen DeSimone | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Oct 2017 | 550 | 13,016 | - | - | Stock Option (right to buy) | |
| Colleen DeSimone | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 16.06 per share. | 23 Oct 2017 | 550 | 0 (0%) | 0% | 16.1 | 8,833 | Common Stock |
| Richard A. Young | None | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 14 Aug 2017 | 3,282 | 420,101 (1%) | 0% | 22 | 72,204 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.59 per share. | 07 Aug 2017 | 2,500 | 0 (0%) | 0% | 23.6 | 58,969 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 07 Aug 2017 | 2,500 | 2,500 (0%) | 0% | 1.0 | 2,525 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2017 | 2,500 | 110,075 | - | - | Stock Option (right to buy) | |
| Richard A. Young | None | Sale of securities on an exchange or to another person at price $ 22.09 per share. | 25 Jul 2017 | 3,282 | 423,383 (1%) | 0% | 22.1 | 72,496 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 25 Jul 2017 | 12,500 | 12,500 (0%) | 0% | 1.0 | 12,625 | Common Stock |
| Eric R. Olson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2017 | 12,500 | 25,025 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.85 per share. | 25 Jul 2017 | 12,500 | 0 (0%) | 0% | 21.9 | 273,125 | Common Stock |
| Marsha H. Fanucci | None | 08 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | ||
| Phillip A. Sharp | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Robert T. Nelsen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Vicki L. Sato | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Srinivas Akkaraju | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2017 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Richard A. Young | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Sanj K. Patel | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Amir H. Nashat | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2017 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Nancy A. Simonian | Director, President & CEO | 10 Feb 2017 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | ||
| Gerald E. Quirk | Chief Legal Officer | 10 Feb 2017 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| Richard A. Young | None | Other type of transaction at price $ 0.00 per share. | 10 Feb 2017 | 106,667 | 426,665 (1%) | 0% | 0 | Common Stock | |
| David A. Roth | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2017 | 63,500 | 63,500 | - | - | Stock Option (right to buy) | |
| Kyle D. Kuvalanka | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2017 | 78,000 | 78,000 | - | - | Stock Option (right to buy) | |
| Eric R. Olson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2017 | 63,500 | 63,500 | - | - | Stock Option (right to buy) | |
| Peter Wirth | None | 27 Jan 2017 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | ||
| Gerald E. Quirk | Chief Legal & Admin. Officer | 27 Sep 2016 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | ||
| Nancy A. Simonian | Director, President & CEO | 16 Sep 2016 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | ||
| Marsha H. Fanucci | Director | 15 Sep 2016 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | ||
| Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2016 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Robert Taylor Nelsen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2016 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Vicki L. Sato | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2016 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Richard A. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2016 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Stephane Bancel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2016 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Sanj K. Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2016 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Amir H. Nashat | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2016 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Phillip A. Sharp | Director | 06 Jul 2016 | 40,000 | 40,000 (0%) | - | - | Common Stock | ||
| Phillip A. Sharp | Director | 06 Jul 2016 | 150,000 | 0 | - | - | Series A-2 Preferred Stock | ||
| Phillip A. Sharp | Director | 06 Jul 2016 | 150,000 | 0 | - | - | Series A-2 Preferred Stock | ||
| Phillip A. Sharp | Director | 06 Jul 2016 | 150,000 | 0 | - | - | Series A-2 Preferred Stock | ||
| Phillip A. Sharp | Director | 06 Jul 2016 | 550,000 | 0 | - | - | Series A-2 Preferred Stock | ||
| Phillip A. Sharp | Director | 06 Jul 2016 | 146,666 | 146,666 (0%) | - | - | Common Stock | ||
| Phillip A. Sharp | Director | 06 Jul 2016 | 40,000 | 40,000 (0%) | - | - | Common Stock | ||
| Phillip A. Sharp | Director | 06 Jul 2016 | 40,000 | 40,000 (0%) | - | - | Common Stock | ||
| Robert Taylor Nelsen | Director, Ten Percent Owner | 06 Jul 2016 | 2,000,000 | 3,813,332 (8%) | - | - | Common Stock | ||
| Robert Taylor Nelsen | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Jul 2016 | 400,000 | 4,637,137 (10%) | - | - | Common Stock | |
| Robert Taylor Nelsen | Director, Ten Percent Owner | 06 Jul 2016 | 423,805 | 4,237,137 (9%) | - | - | Common Stock | ||
| Robert Taylor Nelsen | Director, Ten Percent Owner | 06 Jul 2016 | 1,333,333 | 1,813,332 (4%) | - | - | Common Stock | ||
| Robert Taylor Nelsen | Director, Ten Percent Owner | 06 Jul 2016 | 266,666 | 479,999 (1%) | - | - | Common Stock | ||
| Robert Taylor Nelsen | Director, Ten Percent Owner | 06 Jul 2016 | 1,000,000 | 0 | - | - | Series A-1 Preferred Stock | ||
| Robert Taylor Nelsen | Director, Ten Percent Owner | 06 Jul 2016 | 5,000,000 | 0 | - | - | Series A-2 Preferred Stock | ||
| Robert Taylor Nelsen | Director, Ten Percent Owner | 06 Jul 2016 | 7,500,000 | 0 | - | - | Series A-3 Preferred Stock | ||
| Robert Taylor Nelsen | Director, Ten Percent Owner | 06 Jul 2016 | 1,589,269 | 0 | - | - | Series B Preferred Stock | ||
| Nancy A. Simonian | Director, President and CEO | 06 Jul 2016 | 250,000 | 0 | - | - | Series A-2 Preferred Stock | ||
| Nancy A. Simonian | Director, President and CEO | 06 Jul 2016 | 66,666 | 370,702 (0%) | - | - | Common Stock | ||
| Flynn E James | None | 06 Jul 2016 | 1,186,654 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Flynn E James | None | 06 Jul 2016 | 1,186,654 | 1,186,654 (2%) | - | - | Common Stock | ||
| Flynn E James | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Jul 2016 | 280,000 | 1,466,654 (3%) | - | - | Common Stock | |
| Flynn E James | None | 06 Jul 2016 | 508,566 | 508,566 (1%) | - | - | Common Stock | ||
| Flynn E James | None | 06 Jul 2016 | 508,566 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Flynn E James | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Jul 2016 | 120,000 | 628,566 (1%) | - | - | Common Stock | |
| Stephane Bancel | Director | 06 Jul 2016 | 26,666 | 47,980 (0%) | - | - | Common Stock | ||
| Stephane Bancel | Director | 06 Jul 2016 | 100,000 | 0 | - | - | Series A-2 Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 06 Jul 2016 | 83,129 | 0 | - | - | Series B Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 06 Jul 2016 | 4,366,825 | 0 | - | - | Series B Preferred Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Jul 2016 | 26,153 | 48,320 (0%) | - | - | Common Stock | |
| Amir H. Nashat | Director, Ten Percent Owner | 06 Jul 2016 | 22,167 | 22,167 (0%) | - | - | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | 06 Jul 2016 | 1,164,486 | 1,164,486 (2%) | - | - | Common Stock | ||
| Amir H. Nashat | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 06 Jul 2016 | 373,847 | 1,538,333 (3%) | - | - | Common Stock |